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A Clinical Audit of a Lynch Syndrome Referral Protocol 
A clinical audit of the referral process was conducted on data from between 01.01.2014 
and 31.12.2014 to identify compliance with the Lynch syndrome referral protocol 
developed by the local NHS Trust MMR Group (Figure 1).  
Aim  
Background  
Approximately 14% of patients with colorectal cancer have tumours that exhibit a 
deficiency in mismatch repair (MMR) genes, of which 3% have Lynch syndrome where the 
mutations have germline origin. Lynch syndrome is associated with significant lifetime 
cancer risks, so early diagnosis is required to optimise outcomes (Vasen et al 2015). 
Previously family history assessment was used to identify individuals with Lynch syndrome, 
but a significant proportion were not identified due to familial heterogeneity.; therefore 
routine MMR immunohistochemistry testing of resected tumours (from patients with 
primary colorectal cancer aged 18 to 70 years old) has been practiced at a local NHS Trust 
since 2012. The primary aim of this testing was to inform treatment decision making, since 
the use of adjuvant chemotherapy is not beneficial in treating MMR deficient tumours.  As 
a result of this testing, individuals with Lynch syndrome have been identified. Previous data 
suggests that only a small proportion of these individuals have been referred to clinical 
genetics for counselling on the risks associated with this finding (Adelson et al 2013). 
Results  
Although cases over 70 years old were not included in the audit standard, we found tumours from most patients over 70  years had 
been tested for MMR deficiency (at the clinician’s request to inform treatment decision making), which revealed some important 
findings. The majority of, but not all, tumours from patients who met the Lynch syndrome referral protocol inclusion criteria (based on 
age, diagnosis and treatment) underwent MMR testing; however only 30% of the dMMR cases were referred. Although the proportion 
of patients with MMR (sporadic and germline) mutations is relatively low, the results have major clinical significance, informing decision 
making about both adjuvant treatments and familial screening (where germline mutations have been detected). Recommendations 
have been made to ensure patients whose tumours are MMR deficient are referred to the clinical genetics service for counselling, and 
testing for germline mutations.  Reflexive B-RAF testing is not always carried out to confirm the potential significance of the MMR loss. 
It is important that reflexive BRAF testing is carried out whenever loss of MLH1/PMS2 is identified. High rates of MMR testing were 
requested for cases over the age of 70. Whilst analysis of this data was outside the scope of the audit standard set, these cases 
represent the highest proportion of tumours deficient in MMR; the majority of which have loss of MLH1/PMS2. Thus, there is an 
increased need for reflexive BRAF testing. Based on findings from this and previous clinical audits (including Colling et al., 2015), the 
following actions are recommended for managing patients with primary colorectal carcinoma in 2016: 
1. All cases of primary colorectal adenocarcinoma should have reflexive MMR testing performed at the time of resection. 
2. Cases identified to be dMMR with loss of MLH1 or MLH1/PMS2 should have reflexive BRAF testing. 
3. All cases identified as dMMR (defined as loss of MSH2, MSH2/MSH6, PMS2 as well as MLH1/PMS2 with no BRAF) should be 
referred to the local clinical genetics team for counselling. 
These recommended changes will be prospectively audited throughout 2016. 
Peter Risby1, Dr Richard Colling2, Dr Lai Mun Wang2 and Dr Verna Lavender3 1 Dept. of  Clinical Genetics, 2Dept. of  Pathology, 3 Oxford Brookes University. 
 




A002 MLH1/PMS2 Yes Negative Yes Yes 
A025 MLH1/PMS2 Yes Negative Yes Yes 
A218 MSH2/MSH6 N/A - Yes No 
A028 MLH1/PMS2 Yes Positive No No 
A130 MLH1/PMS2 Yes Positive No No 
A126 MLH1/PMS2 No - Yes No 
A159 MLH1/PMS2 No - Yes No 
A072 PMS2 N/A - Yes No 
A023 MSH2/MSH6 N/A - Yes No 
A077 MSH2/MSH6 N/A - Yes No 
A209 MSH6 N/A - Yes Yes 
A171 MSH6 N/A - Yes No 
 
 Age Group Total MMR Untested MMR Tested 
All Cases 256 41 (16 %) 215 (84 %) 
Under 50 18 3 (17 %) 15 (83 %) 
Aged 50-70 112 14 (12.5 %) 98 (87.5 %) 
Aged over 70* 126 24 (19 %) 102 (81 %) 
Method 
The audit standard used was “that all patients aged between 18 and 70 and treated with 
surgical resection for primary colorectal cancer should have MMR testing, and cases found 
to be mismatch repair deficient (dMMR) should be referred to the clinical genetics service 
for counselling and potential investigation of germline mutations”. Sequential audit 
objectives were developed using the referral protocol. De-identified binomial data were 
summarised using descriptive statistics to analyse the proportion of patients who were 
treated according to the Lynch syndrome referral protocol. Sub-group analysis by age 
stratification was also conducted.  
Figure 1 
 Age Group Total Tested MMR Stable MMR Deficient 
All Cases 215 180 (84 %) 35 (16 %) 
Under 50 15 12 (80 %) 3 (20 %) 
Aged 50-70 98 89 (91 %) 9 (9 %) 
Aged over 70* 102 79 (77.5 %) 23 (22.5 %) 
Table 1. Number of individuals with primary colorectal cancer who had their tumour tested for MMR in 2014 
 Table 2. Number of primary colorectal tumours tested found to be deficient in MMR in 2014 
Table 3. Management of individuals aged 18—70 with dMMR primary colorectal tumours in 2014 (12 cases) 
Conclusions and Recommendations 
